First Tracks Biotherapeutics TRAX
NASDAQ TRAX
$46.56 -0.54 (-1.15%)
At close: Nov 16, 2026 · 4:00 PM EST

First Tracks Biotherapeutics (TRAX) Accumulated Expenses (2024 - 2026)

Updated

First Tracks Biotherapeutics (TRAX) posted Accumulated Expenses of $11.72 million for Q3 2026, up 57.2% from the prior quarter.

Analysis

First Tracks Biotherapeutics (TRAX) Accumulated Expenses (2024 - 2026) Analysis & Trends

At the end of FY2025, First Tracks Biotherapeutics' Accumulated Expenses came in at $25.83 million, down 15.2% from FY2024.

  • In prior years, First Tracks Biotherapeutics' Accumulated Expenses was $30.47 million in FY2024.
  • Quarterly Accumulated Expenses has run from a low of $7.46 million in Q2 2026 to a high of $30.47 million in Q4 2024 over five years.
  • According to Business Quant data, Accumulated Expenses for the three prior quarters was $7.46 million (Q2 2026), $25.62 million (Q1 2026) and $25.83 million (Q4 2025).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,276.89 Bn 1,250.50 Bn 20.46 Bn
2 Johnson & Johnson 681.31 Bn 601.18 Bn 17.30 Bn
3 AbbVie 520.63 Bn 488.64 Bn 13.12 Bn
4 Merck 357.22 Bn 320.16 Bn 13.19 Bn
5 Novartis Ag 310.90 Bn 284.14 Bn -
6 Astrazeneca 285.12 Bn 258.77 Bn 13.26 Bn
7 Amgen 250.23 Bn 201.89 Bn 7.58 Bn
8 Gilead Sciences 207.56 Bn 182.67 Bn 6.73 Bn
9 Pfizer 164.42 Bn 111.77 Bn 12.56 Bn
10 First Tracks Biotherapeutics 1.66 Bn 740.14 Mn -
Historic Data

Historic Data

Download Data
DateValue
Sep 30, 2026 11.72 Mn
Jun 30, 2026 7.46 Mn
Mar 31, 2026 25.62 Mn
Dec 31, 2025 25.83 Mn
Dec 31, 2024 30.47 Mn
API Access

First Tracks Biotherapeutics Accumulated Expenses API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=accumulated-expenses&ticker=TRAX&period=max&api_key=YOUR_API_KEY